Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer

被引:1
|
作者
Alshamsan, Bader [1 ,2 ]
Alshibany, Aisha [1 ]
Elshenawy, Mahmoud A. [1 ,3 ]
Badran, Ahmed [1 ,4 ]
Elhassan, Tusneem [1 ]
Ajarim, Dahish [1 ]
Alsayed, Adher [1 ]
Suleman, Kausar [1 ]
Al-Tweigeri, Taher [1 ]
机构
[1] King Faisal Specialist Hosp & Res Ctr, Ctr Oncol, Med Oncol, Riyadh, Saudi Arabia
[2] Qassim Univ, Dept Med, Coll Med, Qasim, Saudi Arabia
[3] Menoufia Univ, Clin Oncol, Fac Med, Shibin Al Kawm, Egypt
[4] Ain Shams Univ Hosp, Dept Clin Oncol, Cairo, Egypt
来源
关键词
neutrophil-to-lymphocyte ratio; Oncotype Dx recurrence score; early-stage breast cancer; hormonal receptor-positive; human epidermal growth factor receptor 2-negative; node-negative breast cancer; GENE-EXPRESSION; TUMOR-MARKER; CHEMOTHERAPY; SURVIVAL; BENEFIT; RISK; PREDICTION; PROGNOSIS; SUBTYPE; WOMEN;
D O I
10.2147/CMAR.S343549
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The correlation between the preoperative neutrophil-to-lymphocyte ratio (NLR) and Oncotype DX (R) (ODX) recurrence score (RS) has not yet been established. We aimed to investigate the association between NLR and ODX RS in patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) early-stage breast cancer (BC). Patients and Methods: This retrospective study included consecutive patients with HR +/HER2-, node-negative primary BC who underwent surgical tumor resection from 2011 to 2019. Receiver operating characteristic curve analysis was used to obtain an optimal NLR cutoff value. Logistic regression analyses were used to estimate associations between various parameters and ODX RS. Furthermore, the factors significantly associated with the ODX RS in multivariable analysis were incorporated in a separate model and estimated using logistic regression. Results: A total of 160 patients were enrolled. The optimal preoperative NLR cutoff was 2.15. Multivariable analysis revealed that NLR and tumor grade (G1/G2 vs G3) were independent predictive factors of high RS cutoff (>= 26). Moreover, including the two variables yielded a stronger association; patients with low NLR and low-grade tumors were unlikely to have high RS (>= 26; odds ratio [OR] = 0.03, 95% confidence interval [CI]: 0.006-0.154; p < 0.001). Conversely, the presence of any of the following factors made patients unlikely to have low RS (<16; OR = 0.34, 95% CI: 0.16-0.73; p = 0.006): high NLR, high grade, or high Ki-67 levels (>20). Conclusion: NLR is a promising independent predictor of RS. Furthermore, in addition to tumor grade and Ki-67 level, they together are also a potential indicator of high and low RS. However, further studies are required to validate this hypothesis.
引用
收藏
页码:9411 / 9420
页数:10
相关论文
共 50 条
  • [21] Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer
    Kyoko Yorozuya
    Toru Takeuchi
    Miwa Yoshida
    Yukako Mouri
    Junko Kousaka
    Kimihito Fujii
    Shogo Nakano
    Takashi Fukutomi
    Kazuo Hara
    Shu Ichihara
    Yingsong Lin
    Shogo Kikuchi
    [J]. Journal of Cancer Research and Clinical Oncology, 2010, 136 : 939 - 944
  • [22] Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer
    Yorozuya, Kyoko
    Takeuchi, Toru
    Yoshida, Miwa
    Mouri, Yukako
    Kousaka, Junko
    Fujii, Kimihito
    Nakano, Shogo
    Fukutomi, Takashi
    Hara, Kazuo
    Ichihara, Shu
    Lin, Yingsong
    Kikuchi, Shogo
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (06) : 939 - 944
  • [23] Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer
    Rakha, Emad A.
    Agarwal, Devika
    Green, Andrew R.
    Ashankyty, Ibraheem
    Ellis, Ian O.
    Ball, Graham
    Alaskandarany, Mohammed A.
    [J]. HISTOPATHOLOGY, 2017, 70 (04) : 622 - 631
  • [24] Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
    Unal, Caglar
    Ozmen, Tolga
    Ordu, Cetin
    Pilanci, Kezban Nur
    Ilgun, Ahmet Serkan
    Gokmen, Erhan
    Almuradova, Elvina
    Ozdogan, Mustafa
    Guler, Niluefer
    Uras, Cihan
    Kara, Halil
    Demircan, Orhan
    Isik, Selver
    Alco, Gul
    Saip, Pinar
    Aydin, Esra
    Duymaz, Tomris
    Celebi, Filiz
    Yararbas, Kanay
    Soybir, Gursel
    Ozmen, Vahit
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [25] Budget Impact of the Oncotype DX Breast Recurrence Score® Test in Patients with Early Primary Hormone-Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in Germany
    Lux, Michael Patrick
    Minartz, Christof
    Mueller-Huesmann, Harald
    Sandor, Marianar Felicia
    Radeck-Knorre, Sabine
    Neubauer, Aljoscha Steffen
    [J]. BREAST CARE, 2024, 19 (01) : 27 - 33
  • [26] Clinical utility of the 21-gene Oncotype DX® Recurrence Score® (RS) assay in hormone receptor-positive, HER2-negative breast cancer (BC)
    Lau, A.
    Miller, D.
    Davison, D.
    Rothney, M.
    Borgen, P.
    [J]. BREAST, 2017, 32 : S97 - S97
  • [27] Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit Among Women of Different Age Groups With HR-Positive, HER2-Negative, Node-Negative Breast Cancer in the SEER Database
    Cheng, Ran
    Kong, Xiangyi
    Wang, Xiangyu
    Fang, Yi
    Wang, Jing
    [J]. FRONTIERS IN ONCOLOGY, 2020, 10
  • [28] The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer
    Thaker, Nikhil G.
    Hoffman, Karen E.
    Stauder, Michael C.
    Shaitelman, Simona F.
    Strom, Eric A.
    Tereffe, Welela
    Smith, Benjamin D.
    Perkins, George H.
    Huo, Lei
    Munsell, Mark F.
    Pusztai, Lajos
    Buchholz, Thomas A.
    Woodward, Wendy A.
    [J]. SPRINGERPLUS, 2015, 4
  • [29] Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer
    Berdunov, Vladislav
    Millen, Steve
    Paramore, Andrew
    Griffin, Jane
    Reynia, Sarah
    Fryer, Nina
    Brown, Rebecca
    Longworth, Louise
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2022, 14 : 619 - 633
  • [30] Association Between Ki-67 Proliferative Index and Oncotype-Dx Recurrence Score in Hormone Receptor-Positive, HER2-Negative Early Breast Cancers. A Systematic Review of the Literature
    Mooghal, Mehwish
    Khan, Muhammad Ali Akbar
    Samar, Mirza Rameez
    Shaikh, Hafsa
    Valimohammad, Azmina Tajdin
    Idrees, Romana
    Rashid, Yasmin Abdul
    Sattar, Abida K.
    [J]. BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2024, 18